Substance / Medication

Guanfacine

Overview

Active Ingredient
guanfacine
RxNorm CUI
40114

Indications

see Clinical Studies ( 14 ) Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [].

Labeler: REMEDYREPACK INC.Updated: 2026-02-11T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Guanfacine extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to guanfacine extended-release tablets or its inactive ingredients, or other products containing guanfacine. Rash and pruritus have been reported.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

15 trials linked to this intervention

15
Total Trials
0
Recruiting
11
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis.
Yu Sijie, Shen Sihao, Tao Ming · J Child Adolesc Psychopharmacol · 2023
PMID: 36944092Meta-Analysis
Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis.
Ruggiero Simona, Clavenna Antonio, Reale Laura et al. · Eur Neuropsychopharmacol · 2014
PMID: 25156577Meta-Analysis
A Randomized Double-Blind Placebo-Controlled Trial of Guanfacine Extended Release for Aggression and Self-Injurious Behavior Associated With Prader-Willi Syndrome.
Singh Deepan, Silver Michael, Jacob Theresa · Am J Med Genet B Neuropsychiatr Genet · 2025
PMID: 40395104RCT
Methylphenidate, Guanfacine, and Combined Treatment Effects on Electroencephalography Correlates of Spatial Working Memory in Attention-Deficit/Hyperactivity Disorder.
Michelini Giorgia, Lenartowicz Agatha, Diaz-Fong Joel P et al. · J Am Acad Child Adolesc Psychiatry · 2023
PMID: 35963558RCTFull text (PMC)
Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.
Michelini Giorgia, Lenartowicz Agatha, Vera Juan Diego et al. · J Am Acad Child Adolesc Psychiatry · 2023
PMID: 35963559RCTFull text (PMC)
Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Huss Michael, McBurnett Keith, Cutler Andrew J et al. · Eur Neuropsychopharmacol · 2019
PMID: 30064718RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Guanfacine (substance)
SNOMED CT
372507007
UMLS CUI
C0079466
RxNorm CUI
40114
Labeler
REMEDYREPACK INC.

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
15
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.